From the patent:
"Experimental study
Patients of female and male gender characterized by massive hair reduction due to various causes, and also a small number of patients of female gender of postmenopausal age, reporting hair thinning, hair reduction and loss of hair strength were selected. The clinical efficacy of preparation 4 that on previous tests displayed the best characteristics of homogeneity and stability was evaluated .
Treatments :
Lotion A, prepared according to the present example 4 ; Lotion B, comparison, prepared as described in WO 2011/095938 (example 1) and then containing PGE1 and S- equol in 1:1 ratio
Lotion C, containing 7 mg of PGE1 enclosed in liposomes as the only active substance, prepared according to method A;
Lotion D, containing 1,25 mg of DGLA enclosed in liposomes as the only active substance, prepared according to method A.
Groups of patients:
• Group 1: 10 (6 male, 4 female) patients treated for 120 days with 1 ml/day of Lotion A to be applied on a well defined area of the scalp;"
"Experimental study
Patients of female and male gender characterized by massive hair reduction due to various causes, and also a small number of patients of female gender of postmenopausal age, reporting hair thinning, hair reduction and loss of hair strength were selected. The clinical efficacy of preparation 4 that on previous tests displayed the best characteristics of homogeneity and stability was evaluated .
Treatments :
Lotion A, prepared according to the present example 4 ; Lotion B, comparison, prepared as described in WO 2011/095938 (example 1) and then containing PGE1 and S- equol in 1:1 ratio
Lotion C, containing 7 mg of PGE1 enclosed in liposomes as the only active substance, prepared according to method A;
Lotion D, containing 1,25 mg of DGLA enclosed in liposomes as the only active substance, prepared according to method A.
Groups of patients:
• Group 1: 10 (6 male, 4 female) patients treated for 120 days with 1 ml/day of Lotion A to be applied on a well defined area of the scalp;"